| Course | HCR 558 Technical Writing for the Regulatory Professional |
|---|---|
| Module | Module 4 |
| Paper type | Regulatory response letter |
| Length | About 769 words, 5 pages |
| Format | APA 7 student paper |
| School | Arizona State University |
| Program | MS in Clinical Research Management |
| Updated | October 2026 |
Free sample paper for HCR 558 Module 4
Response to FDA Warning Letter: Clinical Investigator, Protocol GLU-204
Student Name
MS in Clinical Research Management, Arizona State University
HCR 558: Technical Writing for the Regulatory Professional
Instructor Name
Month Day, Year
Response to FDA Warning Letter: Clinical Investigator, Protocol GLU-204
Part 1: Analysis of the Warning Letter
The composite letter followed an FDA inspection of a clinical investigator's site in a Phase 2 study of an oral diabetes drug and cited three violations of the investigator's obligations under the IND regulations.
FDA warning letters typically ask for a written response within 15 business days describing the specific steps taken to correct each violation and prevent recurrence, with documentation. A persuasive response therefore cannot argue with findings supported by inspection evidence; it persuades by showing that the investigator understands why each violation matters to participant safety or data integrity and has fixed the system that allowed it.
| Violation | Regulation | What the inspection found | What FDA expects in the response |
|---|---|---|---|
| Failure to conduct the study according to the investigational plan | 21 C.F.R. § 312.60 | Three participants enrolled with HbA1c above the protocol maximum; fasting glucose not checked at two visits | Correction for affected participants, root cause, systemic prevention |
| Failure to maintain adequate and accurate case histories | 21 C.F.R. § 312.62(b) | Dosing times on case report forms did not match source notes for five participants | Data reconciliation, sponsor notification, documentation controls |
| Failure to report changes to the IRB before implementation | 21 C.F.R. § 312.66 | Visit window widened from 3 to 7 days without IRB approval | Retrospective reporting, training, change-control process |
Part 2: The Response Letter
October 12, 2026
Division of Clinical Compliance Evaluation, Office of Scientific Investigations, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
Re: Warning Letter dated September 22, 2026; Protocol GLU-204
Dear Director,
I am writing in response to the Warning Letter dated September 22, 2026, which followed the inspection of my site. I take the findings seriously and accept full responsibility as clinical investigator for the conduct of the study. My responses to each violation follow, with supporting documents listed at the end.
Violation 1: Failure to conduct the investigation according to the investigational plan. I agree with the finding. Three participants were enrolled with HbA1c values above the 10.0% maximum because screening results arrived after randomization and staff relied on a point-of-care value. Fasting glucose was not checked at two visits because the visit checklist omitted it after an amendment. Correction: I reported all three ineligible enrollments to the sponsor and IRB; the sponsor's medical monitor reviewed each participant's safety, and none experienced a related adverse event. Prevention: randomization now requires a second staff member to confirm all central laboratory eligibility values in the electronic system, and visit checklists are regenerated from the current protocol at every amendment. Timeline: implemented October 1, 2026. Effectiveness check: a monthly audit of all new enrollments for six months, with results sent to the sponsor.
Violation 2: Failure to maintain adequate and accurate case histories. I agree with the finding. Dosing times on case report forms were transcribed from memory rather than from participants' diaries. Correction: the coordinator reconciled all case report form entries against source for every participant, and corrected entries were submitted to the sponsor with audit trails. Prevention: a source-to-CRF verification step by a second staff member within five days of each visit, and retraining of all staff on ALCOA principles of data quality. Timeline: reconciliation completed September 30, 2026; training completed October 3, 2026. Effectiveness check: quarterly internal source verification of a 20% sample.
Violation 3: Failure to report changes to the IRB before implementation. I agree with the finding. The visit window was widened in response to a sponsor note that we misread as an approved change. Correction: the change was reported to the IRB, which acknowledged it on October 2, 2026, and all visits now follow the approved 3-day window. Prevention: a written change-control procedure requiring documented IRB approval before any protocol-related change, with the regulatory specialist as gatekeeper. Timeline: procedure effective October 6, 2026. Effectiveness check: review of all protocol changes at each monitoring visit.
I have also completed refresher training in investigator responsibilities and will review the site's corrective actions personally each month for the next year. I welcome any further questions.
Sincerely,
Clinical Investigator
Enclosures: CAPA plan with owners and dates; reconciliation report; training records; revised eligibility and visit checklists; change-control SOP; IRB acknowledgment letter.
Conclusion
Regulatory correspondence is judged by how easily its reader can find each answer (Fossati Wood & Foote, 2009). A strong warning letter response accepts responsibility, answers each violation in the agency's order and shows, with documents and dates, that the underlying system has changed and will be checked. Tone matters as much as content: the letter persuades by being specific, not by being defensive.
References
Assurance of IRB review, 21 C.F.R. § 312.66 (2025).
Fossati Wood, L., & Foote, M. (Eds.). (2009). Targeted regulatory writing techniques: Clinical documents for drugs and biologics. Birkhäuser.
General responsibilities of investigators, 21 C.F.R. § 312.60 (2025).
Recordkeeping and record retention, 21 C.F.R. § 312.62 (2025).
What the HCR 558 Module 4 instructions ask for
The FDA Warning Letter Response is assigned in Week 3 of HCR 558 and due in Week 4, after the module on FDA warning letters, and it is worth 100 points. The syllabus asks for a detailed and persuasive response that demonstrates understanding of the cited regulatory violations, proposes practical, well-supported corrective and preventive actions with timelines for implementation and reassessment and uses the tone and formatting appropriate for correspondence with a federal agency. The letter you answer comes from Canvas, but the approach suits any warning letter: identify each violation and the regulation behind it, decide whether you accept the finding, then answer in the agency's order with root cause, correction, prevention, timeline, evidence and a way to check effectiveness. Warning letters posted on the FDA website show the language and structure the agency uses, which helps you mirror it.
How the HCR 558 Module 4 example is put together
Two parts make up the sample. Its first part analyzes the letter in a table listing each violation, its regulation, what the inspection found and what the agency expects in response, then explains why the response does not contest findings supported by inspection evidence. Part 2 is the response letter, formatted for an FDA office with date, addressee, a reference line and an opening that accepts responsibility. Each violation then gets its own paragraph with the same six parts in the same order: agreement, root cause, correction, prevention, timeline and effectiveness check. The letter closes with a personal commitment and a list of enclosures, and a two-sentence conclusion states what makes such a response persuasive.
HCR 558 Module 4 rubric: what earns full marks
One hundred points ride on the warning letter response. Credit goes to an accurate understanding of each cited violation and its regulation, corrective actions that fix the specific problem, preventive actions that change the system, realistic timelines with reassessment, supporting documentation and a professional, accountable tone in correct letter format. Points are lost when the response disputes well-documented findings, when actions are vague ("staff will be retrained") without content or dates, when root causes are missing, when there is no effectiveness check and when the letter is organized differently from the warning letter. Readers also notice tone; a letter that blames staff or the sponsor reads as weaker than one that takes ownership.
HCR 558 Module 4 help from the desk
List the violations in the warning letter's order and keep that order in your response. For each, write a root cause before you write the fix. Separate correction (fixing what happened) from prevention (stopping it happening again). Give each action a date and an owner. Add an effectiveness check for every violation. Attach evidence and list it. Read a few real warning letter responses to calibrate tone. If you are unsure whether to accept or contest a finding, the desk can talk through the evidence with you. A response that arrives late or misses a violation can lead the agency to escalate, so treat the deadline and completeness as part of the grade.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official Arizona State University document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.
More HCR 558 and MS in Clinical Research Management sample papers
- HCR 558 Module 2: IRB Letter: Response to a Notice of Conditional Approval
- HCR 561 Module 5: Assignment 2: Essay on Vulnerable Populations
- HCR 593 Module 5: Introduction and Background (Review of the Literature)
- HCR 566 Module 2: Capstone Proposal
- HCR 551 Module 3: CAPA Writing Assignment
HCR 558 Module 4 questions, answered
Where can I find a free HCR 558 Module 4 sample paper?
The FDA Warning Letter Response sample is on this page in full, answering three violations with corrective and preventive actions.
How long do you have to respond to an FDA warning letter?
Warning letters typically ask for a written response within 15 business days.
What should each part of a warning letter response include?
Agreement or explanation, root cause, correction, prevention, timeline, evidence and an effectiveness check.
What are common FDA findings against clinical investigators?
Not following the protocol, inadequate case histories and failing to obtain IRB review of changes, under 21 C.F.R. §§ 312.60, 312.62 and 312.66.
What is the difference between correction and prevention in a CAPA?
Correction fixes what went wrong; prevention changes the system so it does not happen again.